Financials data is unavailable for this security.
View more
Year on year Skye Bioscience Inc 's net income fell 93.23% from a loss of 19.48m to a larger loss of 37.64m despite flat revenues.
| Gross margin | -- |
|---|---|
| Net profit margin | -- |
| Operating margin | -- |
| Return on assets | -94.50% |
|---|---|
| Return on equity | -130.08% |
| Return on investment | -129.40% |
More ▼
Cash flow in USDView more
In 2023, Skye Bioscience Inc increased its cash reserves by 727.52%, or 9.09m. Cash Flow from Financing totalled 16.44m or -- of revenues. In addition the company used 13.95m for operations while cash from investing totalled 6.60m.
| Cash flow per share | -1.94 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.59 |
|---|---|
| Tangible book value per share | 2.59 |
More ▼
Balance sheet in USDView more
| Current ratio | 6.07 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.0667 |
|---|---|
| Total debt/total capital | 0.0626 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 38.74%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 45.15 |
